Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alba A Brandes

Showing results (161-170 of 178) with videos related to

Pageof 18
Sort By:
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
The Lancet. Oncology|June 6, 2020
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groupJason Fangusaro, Olaf Witt, Pablo Hernáiz Driever, et al.
The Lancet. Digital Health|October 24, 2021
Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort studyChandrakanth Jayachandran Preetha, Hagen Meredig, Gianluca Brugnara, et al.
The New England Journal of Medicine|March 16, 2017
Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaJames R Perry, Normand Laperriere, Christopher J O'Callaghan, et al.
BMC Medicine|November 22, 2019
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialMaria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
The Lancet. Oncology|February 29, 2024
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort studyAditya Rastogi, Gianluca Brugnara, Martha Foltyn-Dumitru, et al.
Lancet (London, England)|September 22, 2009
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trialAndrés J M Ferreri, Michele Reni, Marco Foppoli, et al.
The Oncologist|January 22, 2026
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysisOgechukwu A Asogwa, Linda Dirven, Neil K Aaronson, et al.
Pageof 18

Showing results (161-170 of 178) with videos related to

Sort By:
Pageof 18
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
The Lancet. Oncology|June 6, 2020
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groupJason Fangusaro, Olaf Witt, Pablo Hernáiz Driever, et al.
The Lancet. Digital Health|October 24, 2021
Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort studyChandrakanth Jayachandran Preetha, Hagen Meredig, Gianluca Brugnara, et al.
The New England Journal of Medicine|March 16, 2017
Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaJames R Perry, Normand Laperriere, Christopher J O'Callaghan, et al.
BMC Medicine|November 22, 2019
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialMaria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
The Lancet. Oncology|February 29, 2024
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort studyAditya Rastogi, Gianluca Brugnara, Martha Foltyn-Dumitru, et al.
Lancet (London, England)|September 22, 2009
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trialAndrés J M Ferreri, Michele Reni, Marco Foppoli, et al.
The Oncologist|January 22, 2026
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysisOgechukwu A Asogwa, Linda Dirven, Neil K Aaronson, et al.
Pageof 18